Benjamin Kasenda

5.2k total citations
64 papers, 1.9k citations indexed

About

Benjamin Kasenda is a scholar working on Neurology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Benjamin Kasenda has authored 64 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Neurology, 19 papers in Oncology and 17 papers in Pathology and Forensic Medicine. Recurrent topics in Benjamin Kasenda's work include CNS Lymphoma Diagnosis and Treatment (20 papers), Lymphoma Diagnosis and Treatment (17 papers) and Health Systems, Economic Evaluations, Quality of Life (12 papers). Benjamin Kasenda is often cited by papers focused on CNS Lymphoma Diagnosis and Treatment (20 papers), Lymphoma Diagnosis and Treatment (17 papers) and Health Systems, Economic Evaluations, Quality of Life (12 papers). Benjamin Kasenda collaborates with scholars based in Switzerland, Germany and United Kingdom. Benjamin Kasenda's co-authors include Matthias Briel, Gerald Illerhaus, Elisabeth Schorb, Martin Gore, James Larkin, Juan Martín-Liberal, Jürgen Finke, Stefan Diem, Kristina Fritsch and Lavinia Spain and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Benjamin Kasenda

62 papers receiving 1.9k citations

Peers

Countries citing papers authored by Benjamin Kasenda

Since Specialization

Citations

This map shows the geographic impact of Benjamin Kasenda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Kasenda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Kasenda more than expected).

Fields of papers citing papers by Benjamin Kasenda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Kasenda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Kasenda. The network helps show where Benjamin Kasenda may publish in the future.

Co-authorship network of co-authors of Benjamin Kasenda

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Kasenda. A scholar is included among the top collaborators of Benjamin Kasenda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Kasenda. Benjamin Kasenda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020 2023 ·International Journal of Cancer ·Viktoria Gloy, Andreas M. Schmitt, (unknown), Julian Hirt, Cathrine Axfors, (unknown), Tiago Pereira, Clara Locher, (unknown), (unknown), Mark P. Lythgoe, Amanda K. Herbrand, Benjamin Kasenda, Lars G. Hemkens	24
2	Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK) 2023 ·BMJ Open ·Stefanie Hayoz, Benjamin Kasenda, (unknown), Christoph Kopp, Sämi Schär, Beat Thürlimann, Roger von Moos, Miklos Pless	2
3	Characteristics and survival of patients with cancer with intended off-label use—a cohort study 2022 ·BMJ Open ·Andreas M. Schmitt, Martin A. Walter, Amanda K. Herbrand, (unknown), Giusi Moffa, Urban Novak, Lars G. Hemkens, Benjamin Kasenda	1
4	Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy 2020 ·Journal of Molecular Diagnostics ·Manuel Montesinos‐Rongen, Anna Brunn, Armin Tuchscherer, Peter Borchmann, Elisabeth Schorb, Benjamin Kasenda, Janine Altmüller, Gerald Illerhaus, Maximilian I. Ruge, Mohammad Maarouf, Reinhard Büttner, Martin‐Leo Hansmann, Michael Hallek, Marco Prinz, Reiner Siebert, Martina Deckert	13
5	Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation 2019 ·PLoS ONE ·Benjamin Speich, Nadine Schur, (unknown), Belinda von Niederhäusern, Lars G. Hemkens, Stefan Schandelmaier, Alain Amstutz, Benjamin Kasenda, Christiane Pauli‐Magnus, (unknown), Yuki Tomonaga, (unknown), Alain Nordmann, Erik von Elm, Matthias Briel, Matthias Schwenkglenks	9
6	Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients 2019 ·BMC Cancer ·Elisabeth Schorb, Jürgen Finke, Gabriele Ihorst, Benjamin Kasenda, Heidi Fricker, Gerald Illerhaus	15
7	3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck – a multicentre, retrospective analysis 2019 ·Radiation Oncology ·(unknown), Oliver Riesterer, Urs R. Meier, Alexandros Papachristofilou, Benjamin Kasenda, Miklos Pless, Sacha I. Rothschild	34
8	ALK-negative anaplastic large cell lymphoma arising in the thrombus of an aortic prosthesis preceeded by clonally related lymphomatoid papulosis 2019 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Thomas Menter, Veronika Ballová, Clemens B. Caspar, Thomas Wolff, Benjamin Kasenda, Gad Singer, Darius Juškevičius, Alexandar Tzankov, Stefan Dirnhofer	8
9	Induction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Diagnosed PCNSL - a Multicenter Retrospective Analysis on Feasibility and Effectiveness in Routine Clinical Practice 2017 ·Blood ·Elisabeth Schorb, (unknown), Benjamin Kasenda, Teresa Calimeri, Kim Linton, Jeffery Smith, (unknown), Deborah Yallop, (unknown), Alberto Fabbri, (unknown), Gerald Illerhaus, Kate Cwynarski, Andrés J.M. Ferreri	2
10	3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis 2017 ·Annals of Oncology ·Sacha I. Rothschild, (unknown), Oliver Riesterer, Urs R. Meier, Alexandros Papachristofilou, Benjamin Kasenda, Miklos Pless	1
11	Multivariable fractional polynomial interaction to investigate continuous effect modifiers in a meta-analysis on higher versus lower PEEP for patients with ARDS 2016 ·BMJ Open ·Benjamin Kasenda, Willi Sauerbrei, Patrick Royston, Alain Mercat, Arthur S. Slutsky, (unknown), Gordon Guyatt, Laurent Brochard, Jean-Christophe M. Richard, Thomas E. Stewart, Maureen O. Meade, Matthias Briel	15
12	Dynamics of neutrophil to lymphocyte ratio (NLR) predict effectiveness of PD1/PDL1 inhibition 2016 ·Annals of Oncology ·Michele Moschetta, Benjamin Kasenda, Gabriel Mak, Mark Voskoboynik, (unknown), Saeed Rafii, Vincenzo Formica, Hendrik‐Tobias Arkenau	2
13	High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix) 2016 ·BMC Cancer ·Elisabeth Schorb, Jürgen Finke, Andrés J.M. Ferreri, Gabriele Ihorst, (unknown), Benjamin Kasenda, Kristina Fritsch, Heidi Fricker, Elvira Burger, Olga Grishina, Elke Valk, Emanuele Zucca, Gerald Illerhaus	43
14	A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable 2016 ·Journal of Clinical Epidemiology ·Matthias Briel, Kelechi Kalu Olu, Erik von Elm, Benjamin Kasenda, Reem Alturki, Arnav Agarwal, Neera Bhatnagar, Stefan Schandelmaier	119
15	Randomized trials addressing a similar question are commonly published after a trial stopped early for benefit 2016 ·Journal of Clinical Epidemiology ·M. Hassan Murad, Gordon Guyatt, Juan Pablo Domecq, Robin W.M. Vernooij, Patricia J. Erwin, Joerg J Meerpohl, Gabriela Prutsky, Elie A. Akl, (unknown), Dirk Bassler, Stefan Schandelmaier, Stephen D. Walter, Jason W. Busse, Benjamin Kasenda, Gennaro Pagano, Héctor Pardo‐Hernández, Víctor M. Montori, Zhen Wang, Matthias Briel	7
16	Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study 2014 ·BMC Cancer ·Benjamin Kasenda, (unknown), Dieter Koeberle, Bernhard C. Pestalozzi, Markus Borner, Richard Herrmann, Lorenz Jost, Andreas Lohri, Viviane Hess	37
17	The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients 2012 ·Annals of Hematology ·Benjamin Kasenda, (unknown), Petra Thürmann, (unknown), Hendrik Veelken, Kristina Fritsch, Elisabeth Schorb, Jürgen Finke, Dirk Lebiedz, Gerald Illerhaus	13
18	Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma—a long-term follow-up study 2012 ·Annals of Oncology ·Benjamin Kasenda, Elisabeth Schorb, Kristina Fritsch, Jürgen Finke, Gerald Illerhaus	67
19	Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly 2011 ·Annals of Oncology ·Kristina Fritsch, Benjamin Kasenda, Claudia Hader, Guido Nikkhah, Marco Prinz, (unknown), Stefan Haug, Gabriele Ihorst, Jürgen Finke, Gerald Illerhaus	98
20	The stromal cell‐derived factor‐1α dependent migration of human cord blood CD34⁺ haematopoietic stem and progenitor cells switches from protein kinase C (PKC)‐α dependence to PKC‐α independence upon prolonged culture in the presence of Flt3‐ligand and interleukin‐6 2008 ·British Journal of Haematology ·Benjamin Kasenda, Susannah H. Kassmer, Bernd Niggemann, Sven Schiermeier, Wolfgang Hatzmann, Kurt S. Zänker, Thomas Dittmar	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact